MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer
暂无分享,去创建一个
H. Lenz | E. Mitchell | A. Parikh | N. Choong | J. Knost | C. Mancao | F. Scappaticci | I. Bosanac | L. Yau | F. Lee | H. Koh